Literature DB >> 22029952

Inhibition of 5α-reductase in the nucleus accumbens counters sensorimotor gating deficits induced by dopaminergic activation.

Paola Devoto1, Roberto Frau, Valentina Bini, Giuliano Pillolla, Pierluigi Saba, Giovanna Flore, Marta Corona, Francesco Marrosu, Marco Bortolato.   

Abstract

Cogent evidence highlights a key role of neurosteroids and androgens in schizophrenia. We recently reported that inhibition of steroid 5α-reductase (5αR), the rate-limiting enzyme in neurosteroid synthesis and androgen metabolism, elicits antipsychotic-like effects in humans and animal models, without inducing extrapyramidal side effects. To elucidate the anatomical substrates mediating these effects, we investigated the contribution of peripheral and neural structures to the behavioral effects of the 5αR inhibitor finasteride (FIN) on the prepulse inhibition (PPI) of the acoustic startle reflex (ASR), a rat paradigm that dependably simulates the sensorimotor gating impairments observed in schizophrenia and other neuropsychiatric disorders. The potential effect of drug-induced ASR modifications on PPI was excluded by measuring this index both as percent (%PPI) and absolute values (ΔPPI). In both orchidectomized and sham-operated rats, FIN prevented the %PPI deficits induced by the dopamine (DA) receptor agonists apomorphine (APO, 0.25mg/kg, SC) and d-amphetamine (AMPH, 2.5mg/kg, SC), although the latter effect was not corroborated by ΔPPI analysis. Conversely, APO-induced PPI deficits were countered by FIN infusions in the brain ventricles (10μg/1μl) and in the nucleus accumbens (NAc) shell and core (0.5μg/0.5μl/side). No significant PPI-ameliorating effect was observed following FIN injections in other brain regions, including dorsal caudate, basolateral amygdala, ventral hippocampus and medial prefrontal cortex, although a statistical trend was observed for the latter region. The efflux of DA in NAc was increased by systemic, but not intracerebral FIN administration. Taken together, these findings suggest that the role of 5αR in gating regulation is based on post-synaptic mechanisms in the NAc, and is not directly related to alterations in DA efflux in this region.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22029952      PMCID: PMC3432701          DOI: 10.1016/j.psyneuen.2011.09.018

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  92 in total

1.  Inhibition of basal and stress-induced dopamine release in the cerebral cortex and nucleus accumbens of freely moving rats by the neurosteroid allopregnanolone.

Authors:  C Motzo; M L Porceddu; G Maira; G Flore; A Concas; L Dazzi; G Biggio
Journal:  J Psychopharmacol       Date:  1996-01       Impact factor: 4.153

2.  Negative correlation between negative symptoms of schizophrenia and testosterone levels.

Authors:  R O Goyal; R Sagar; A C Ammini; M L Khurana; A G Alias
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

3.  Improvement of general symptoms in a chronic psychotic patient treated with finasteride: case report.

Authors:  D Koethe; M Bortolato; D Piomelli; F M Leweke
Journal:  Pharmacopsychiatry       Date:  2008-05       Impact factor: 5.788

4.  Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results.

Authors:  F X Castellanos; E J Fine; D Kaysen; W L Marsh; J L Rapoport; M Hallett
Journal:  Biol Psychiatry       Date:  1996-01-01       Impact factor: 13.382

5.  The effects of inhibitors of GABAergic transmission and stress on brain and plasma allopregnanolone concentrations.

Authors:  M L Barbaccia; G Roscetti; M Trabucchi; R H Purdy; M C Mostallino; A Concas; G Biggio
Journal:  Br J Pharmacol       Date:  1997-04       Impact factor: 8.739

6.  The anxiolytic-like effects of allopregnanolone vary as a function of intracerebral microinfusion site: the amygdala, medial prefrontal cortex, or hippocampus.

Authors:  Elif Engin; Dallas Treit
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

7.  Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex.

Authors:  Noemí Santana; Guadalupe Mengod; Francesc Artigas
Journal:  Cereb Cortex       Date:  2008-08-09       Impact factor: 5.357

8.  Estrogen regulation of dopamine release in the nucleus accumbens: genomic- and nongenomic-mediated effects.

Authors:  T L Thompson; R L Moss
Journal:  J Neurochem       Date:  1994-05       Impact factor: 5.372

Review 9.  Gender differences in the prescribing of antipsychotic drugs.

Authors:  Mary V Seeman
Journal:  Am J Psychiatry       Date:  2004-08       Impact factor: 18.112

10.  On the origin of cortical dopamine: is it a co-transmitter in noradrenergic neurons?

Authors:  Paola Devoto; Giovanna Flore
Journal:  Curr Neuropharmacol       Date:  2006-04       Impact factor: 7.363

View more
  28 in total

1.  Regional distribution of 5α-reductase type 2 in the adult rat brain: an immunohistochemical analysis.

Authors:  M Paola Castelli; Alberto Casti; Angelo Casu; Roberto Frau; Marco Bortolato; Saturnino Spiga; Maria Grazia Ennas
Journal:  Psychoneuroendocrinology       Date:  2012-07-08       Impact factor: 4.905

Review 2.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

3.  5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder.

Authors:  Pedro E Martinez; David R Rubinow; Lynnette K Nieman; Deloris E Koziol; A Leslie Morrow; Crystal E Schiller; Dahima Cintron; Karla D Thompson; Khursheed K Khine; Peter J Schmidt
Journal:  Neuropsychopharmacology       Date:  2013-08-14       Impact factor: 7.853

4.  Allopregnanolone is required for prepulse inhibition deficits induced by D1 dopamine receptor activation.

Authors:  Laura J Mosher; Roberto Cadeddu; Sabrina Yen; Jeffrey L Staudinger; Francesco Traccis; Stephen C Fowler; Jamie L Maguire; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2019-06-14       Impact factor: 4.905

Review 5.  Update: studies of prepulse inhibition of startle, with particular relevance to the pathophysiology or treatment of Tourette Syndrome.

Authors:  Neal R Swerdlow
Journal:  Neurosci Biobehav Rev       Date:  2012-09-24       Impact factor: 8.989

6.  Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Authors:  Roberto Frau; Federico Abbiati; Valentina Bini; Alberto Casti; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Schizophr Res       Date:  2015-05-18       Impact factor: 4.939

7.  Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice.

Authors:  Roberto Frau; Giuliano Pillolla; Valentina Bini; Simone Tambaro; Paola Devoto; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2012-08-09       Impact factor: 4.905

8.  The Neurosteroidogenic Enzyme 5α-Reductase Mediates Psychotic-Like Complications of Sleep Deprivation.

Authors:  Roberto Frau; Valentina Bini; Alessio Soggiu; Simona Scheggi; Alessandra Pardu; Silvia Fanni; Paola Roncada; Monica Puligheddu; Francesco Marrosu; Donatella Caruso; Paola Devoto; Marco Bortolato
Journal:  Neuropsychopharmacology       Date:  2017-02-15       Impact factor: 7.853

9.  Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors.

Authors:  Laura J Mosher; Sean C Godar; Marc Morissette; Kenneth M McFarlin; Simona Scheggi; Carla Gambarana; Stephen C Fowler; Thérèse Di Paolo; Marco Bortolato
Journal:  Psychoneuroendocrinology       Date:  2018-02-16       Impact factor: 4.905

10.  Sociocommunicative and sensorimotor impairments in male P2X4-deficient mice.

Authors:  Letisha R Wyatt; Sean C Godar; Sheraz Khoja; Michael W Jakowec; Ronald L Alkana; Marco Bortolato; Daryl L Davies
Journal:  Neuropsychopharmacology       Date:  2013-04-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.